🔎 Trials Near Me

Home › Post-COVID Conditions (Long COVID) › NCT05866952

Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection

RecruitingObservational studyHealthy volunteers welcome

Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection

Who can join

Ages 18 to 99 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Age ≥ 18
* Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \> 3 months ago or no previous history of SARS-CoV-2 infection (control group only)
* Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)
* New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)

Exclusion Criteria:

* SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months
* Inability to provide consent or non-English speaking
* Pregnancy
* Any respiratory infection in last 4 weeks
* PFT relative contraindications
* History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism
* Active malignancy undergoing treatment or history of malignancy involving the lung

About the study

Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations

What is being tested

Sponsor: Tufts Medical Center · Participants: 40 · Started: Jun 5, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05866952

Locations in the U.S.

MassachusettsTufts Medical Center, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.